Study S001167

A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT07160257
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 56
Start: 2025-08-05
Primary completion: 2026-11-15
Lead sponsor: Amgen
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:Maridebart cafraglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Change from Baseline in M-value from Hyperinsulinemic-euglycemic Clamp at Week 25 [Baseline and Week 25]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.